Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01096017 | To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study | PHASE3 | COMPLETED | 24 | — | — | Mar 1, 2010 | Apr 1, 2010 | Aug 31, 2012 | 1 | Japan |
| NCT00244608 | A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler® | PHASE3 | COMPLETED | 100 | — | — | May 1, 2005 | Mar 1, 2007 | Jan 24, 2011 | 22 | Denmark, France +4 |
FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler® |
| 2 | EXPERIMENTAL | salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI |
| Name | Type | Description |
|---|---|---|
| Terbutaline Turbuhaler® | DRUG | 0.4 mg, inhalation, single dose |
| Salbutamol pMDI | DRUG | 200 μg, inhalation, single dose |
| pMDI placebo pMDI | OTHER | Placebo pMDI 2 inhalations |
| Placebo Turbuhaler® | OTHER | Placebo Turbuhaler 1 inhalation |
| Budesonide/Formoterol Turbuhaler | DRUG | - |
| Budesonide Turbuhaler (Pulmicort) | DRUG | - |
| Terbutaline Turbuhaler | DRUG | - |
Inclusion Criteria: * On ICS for at least 3 months from Visit 2 and with a prescribed constant dose during the 4 weeks prior to Visit 2 * Forced Expiratory Volume in 1 Second (FEV1) of at least 50 % of predicted normal value pre-bronchodilator * Reversible airway obstruction according to reversibil...